Evidence map›Paper›PMID 27738494›Full record

ArticleGenes & cancer2016

ADAM17 in tumor associated leukocytes regulates inflammatory mediators and promotes mammary tumor formation.

Laura R Bohrer, Thomas S Chaffee, Pavlina Chuntova, Nicholas J Brady, Patrice M Witschen, Sarah E Kemp, Andrew C Nelson, Bruce Walcheck, Kathryn L Schwertfeger

Open access · diamondAbstract read
In one paragraph

Article in Genes & cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Laura R Bohrer *Department of Lab Medicine and Pathology, University of Minnesota, MN, USA.
Thomas S Chaffee *Department of Lab Medicine and Pathology, University of Minnesota, MN, USA.
Pavlina ChuntovaMicrobiology, Immunology and Cancer Biology Graduate Program, University of Minnesota, MN, USA.
Nicholas J BradyMicrobiology, Immunology and Cancer Biology Graduate Program, University of Minnesota, MN, USA.
Patrice M WitschenDepartment of Veterinary and Biomedical Sciences, University of Minnesota, MN, USA.
Sarah E KempDepartment of Lab Medicine and Pathology, University of Minnesota, MN, USA.
Andrew C NelsonDepartment of Lab Medicine and Pathology, University of Minnesota, MN, USA.
Bruce WalcheckDepartment of Veterinary and Biomedical Sciences, University of Minnesota, MN, USA.
Kathryn L SchwertfegerDepartment of Lab Medicine and Pathology, University of Minnesota, MN, USA.
University of Minnesota · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
Contributions of FGFR-Mediated Tumor-Stromal Interactions to Breast Cancer Growth and ProgressionR01CA215052 · NCI · UNIVERSITY OF MINNESOTA · PI Kathryn L Schwertfeger · 2017 to 2026
$3.6M
Inflammation in Breast Cancer Initiation and PromotionR01CA132827 · NCI · UNIVERSITY OF MINNESOTA · PI SCHWERTFEGER, KATHRYN L · 2011 to 2015
$1.5M
(PQB-3) Characterization of the immune response during mammary tumor initiationR21CA184541 · NCI · UNIVERSITY OF MINNESOTA · PI SCHWERTFEGER, KATHRYN L · 2014 to 2015
$364k
NCATS NIH HHS UL1 TR000114NCI NIH HHS R01 CA132827NCI NIH HHS R01 CA215052NCI NIH HHS R21 CA184541
6 · The paper itself

Abstract

The presence of inflammatory cells within the tumor microenvironment has been tightly linked to mammary tumor formation and progression. Specifically, interactions between tumor cells and infiltrating macrophages can contribute to the generation of a pro-tumorigenic microenvironment. Understanding the complex mechanisms that drive tumor cell-macrophage cross-talk will ultimately lead to the development of approaches to prevent or treat early stage breast cancers. As described here, we demonstrate that the cell surface protease a disintegrin and metalloproteinase 17 (ADAM17) is expressed by macrophages in mammary tumors and contributes to regulating the expression of pro-inflammatory mediators, including inflammatory cytokines and the inflammatory mediator cyclooxygenase-2 (Cox-2). Furthermore, we demonstrate that ADAM17 is expressed on leukocytes, including macrophages, within polyoma middle T (PyMT)-derived mammary tumors. Genetic deletion of ADAM17 in leukocytes resulted in decreased onset of mammary tumor growth, which was associated with reduced expression of the Cox-2 within the tumor. These findings demonstrate that ADAM17 regulates key inflammatory mediators in macrophages and that leukocyte-specific ADAM17 is an important promoter of mammary tumor initiation. Understanding the mechanisms associated with early stage tumorigenesis has implications for the development of preventive and/or treatment strategies for early stage breast cancers.

Indexed as

ADAM17Breast cancerCox-2inflammationmacrophage

Identifiers

PMID27738494
PMCPMC5059114
OpenAlexW2585581495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.